- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 471/10 - Spiro-condensed systems
Patent holdings for IPC class C07D 471/10
Total number of patents in this class: 2416
10-year publication summary
|
114
|
123
|
144
|
148
|
144
|
159
|
177
|
195
|
193
|
174
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Bristol-myers Squibb Company | 4826 |
57 |
| F. Hoffmann-La Roche AG | 7937 |
56 |
| Merck Sharp & Dohme LLC | 3732 |
53 |
| Novartis AG | 10612 |
52 |
| Merck Patent GmbH | 5752 |
45 |
| Pfizer Inc. | 3401 |
38 |
| Hoffmann-La Roche Inc. | 3546 |
36 |
| Boehringer Ingelheim International GmbH | 4636 |
32 |
| Incyte Corporation | 1039 |
23 |
| Syngenta Participations AG | 1730 |
22 |
| Janssen Pharmaceutica N.V. | 3358 |
21 |
| The Regents of the University of Michigan | 4793 |
21 |
| Astellas Pharma Inc. | 1057 |
21 |
| H. Lundbeck A/S | 1237 |
21 |
| Arvinas Operations, Inc. | 244 |
21 |
| Merck Sharp & Dohme Corp. | 2189 |
20 |
| Takeda Pharmaceutical Company Limited | 2721 |
19 |
| Celgene Quanticel Research, Inc. | 162 |
19 |
| Amgen Inc. | 4256 |
16 |
| Vertex Pharmaceuticals Incorporated | 1630 |
16 |
| Other owners | 1807 |